Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever
© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
BACKGROUND: Late-relapsing hepatitis after yellow fever (LHep-YF) during the convalescent phase of the disease has been described during recent yellow fever (YF) outbreaks in Brazil. LHep-YF is marked by a rebound in liver enzymes and nonspecific clinical manifestations around 46-60 days after YF symptom onset.
METHODS: Here we have characterized the clinical course and risk factors for LHep-YF using data from a representative cohort of patients who survived YF in Brazil, 2017-2018. A total of 221 YF-positive patients were discharged from the infectious disease reference hospital in Minas Gerais and were followed up at 30, 45, and 60 days post-symptom onset.
RESULTS: From 46 to 60 days post-symptom onset, 16% of YF patients (n = 36/221) exhibited a rebound of aminotransferases (aspartate aminotransferase or alanine aminotransferase >500 IU/L), alkaline phosphatase, and total bilirubin levels. Other etiologies of liver inflammation such as infectious hepatitis, autoimmune hepatitis, and metabolic liver disease were ruled out. Jaundice, fatigue, headache, and low platelet levels were associated with LHep-YF. Demographic factors, clinical manifestations, laboratory tests, ultrasound findings, and viral load during the acute phase of YF were not associated with the occurrence of LHep-YF.
CONCLUSIONS: These findings provide new data on the clinical course of Late-relapsing hepatitis during the convalescent phase of YF and highlight the need for extended patient follow-up after acute YF.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:77 |
|---|---|
| Enthalten in: |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 77(2023), 4 vom: 22. Aug., Seite 565-573 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Convalescent phase |
|---|
| Anmerkungen: |
Date Completed 24.08.2023 Date Revised 24.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1093/cid/ciad249 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356029980 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356029980 | ||
| 003 | DE-627 | ||
| 005 | 20231226065608.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/cid/ciad249 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356029980 | ||
| 035 | |a (NLM)37099356 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rezende, Izabela Mauricio de |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Characterization and Investigation of Risk Factors for Late-Relapsing Hepatitis After Yellow Fever |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.08.2023 | ||
| 500 | |a Date Revised 24.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a BACKGROUND: Late-relapsing hepatitis after yellow fever (LHep-YF) during the convalescent phase of the disease has been described during recent yellow fever (YF) outbreaks in Brazil. LHep-YF is marked by a rebound in liver enzymes and nonspecific clinical manifestations around 46-60 days after YF symptom onset | ||
| 520 | |a METHODS: Here we have characterized the clinical course and risk factors for LHep-YF using data from a representative cohort of patients who survived YF in Brazil, 2017-2018. A total of 221 YF-positive patients were discharged from the infectious disease reference hospital in Minas Gerais and were followed up at 30, 45, and 60 days post-symptom onset | ||
| 520 | |a RESULTS: From 46 to 60 days post-symptom onset, 16% of YF patients (n = 36/221) exhibited a rebound of aminotransferases (aspartate aminotransferase or alanine aminotransferase >500 IU/L), alkaline phosphatase, and total bilirubin levels. Other etiologies of liver inflammation such as infectious hepatitis, autoimmune hepatitis, and metabolic liver disease were ruled out. Jaundice, fatigue, headache, and low platelet levels were associated with LHep-YF. Demographic factors, clinical manifestations, laboratory tests, ultrasound findings, and viral load during the acute phase of YF were not associated with the occurrence of LHep-YF | ||
| 520 | |a CONCLUSIONS: These findings provide new data on the clinical course of Late-relapsing hepatitis during the convalescent phase of YF and highlight the need for extended patient follow-up after acute YF | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a convalescent phase | |
| 650 | 4 | |a hepatitis | |
| 650 | 4 | |a relapsing hepatitis | |
| 650 | 4 | |a viral persistence | |
| 650 | 4 | |a yellow fever | |
| 650 | 7 | |a Yellow Fever Vaccine |2 NLM | |
| 700 | 1 | |a McClure, Max A |e verfasserin |4 aut | |
| 700 | 1 | |a Pereira, Leonardo S |e verfasserin |4 aut | |
| 700 | 1 | |a Fradico, Jordana R B |e verfasserin |4 aut | |
| 700 | 1 | |a Cenachi, Adriana R C |e verfasserin |4 aut | |
| 700 | 1 | |a Moura, Alexandre S |e verfasserin |4 aut | |
| 700 | 1 | |a Paladino, Luísa L de A |e verfasserin |4 aut | |
| 700 | 1 | |a Dutra, Maria Rita T |e verfasserin |4 aut | |
| 700 | 1 | |a Alves, Pedro A |e verfasserin |4 aut | |
| 700 | 1 | |a Xavier, Marcelo A P |e verfasserin |4 aut | |
| 700 | 1 | |a Said, Rodrigo F do C |e verfasserin |4 aut | |
| 700 | 1 | |a Ramalho, Dario B |e verfasserin |4 aut | |
| 700 | 1 | |a Gama, Thaysa D P |e verfasserin |4 aut | |
| 700 | 1 | |a Martins-Filho, Olindo A |e verfasserin |4 aut | |
| 700 | 1 | |a Monath, Thomas P |e verfasserin |4 aut | |
| 700 | 1 | |a Teixeira-Carvalho, Andréa |e verfasserin |4 aut | |
| 700 | 1 | |a Drumond, Betânia P |e verfasserin |4 aut | |
| 700 | 1 | |a LaBeaud, Angelle D |e verfasserin |4 aut | |
| 700 | 0 | |a Yellow Fever Collaborative Group |e verfasserin |4 aut | |
| 700 | 1 | |a Castro Bragato, Alexandre Maurício |e investigator |4 oth | |
| 700 | 1 | |a Araújo, Argus Leão |e investigator |4 oth | |
| 700 | 1 | |a de Almeida Faria, Flávio Augusto |e investigator |4 oth | |
| 700 | 1 | |a Penido, Indiara |e investigator |4 oth | |
| 700 | 1 | |a Menezes, Letícia |e investigator |4 oth | |
| 700 | 1 | |a Rabelo, Livia Frota |e investigator |4 oth | |
| 700 | 1 | |a Pamplona, Livia |e investigator |4 oth | |
| 700 | 1 | |a da Cunha Melo, Lívia Fulgêncio |e investigator |4 oth | |
| 700 | 1 | |a Fonte Boa, Lívia Soares Coelho |e investigator |4 oth | |
| 700 | 1 | |a Dos Santos, Lívia Zignago Moreira |e investigator |4 oth | |
| 700 | 1 | |a de Paula, Ludmila |e investigator |4 oth | |
| 700 | 1 | |a Marçal, Marcelle Cardoso |e investigator |4 oth | |
| 700 | 1 | |a Albuquerque, Natalia Soares |e investigator |4 oth | |
| 700 | 1 | |a Macedo, Rodrigo |e investigator |4 oth | |
| 700 | 1 | |a Araújo, Tayrine |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |d 1992 |g 77(2023), 4 vom: 22. Aug., Seite 565-573 |w (DE-627)NLM012603007 |x 1537-6591 |7 nnns |
| 773 | 1 | 8 | |g volume:77 |g year:2023 |g number:4 |g day:22 |g month:08 |g pages:565-573 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/cid/ciad249 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 77 |j 2023 |e 4 |b 22 |c 08 |h 565-573 | ||